NephroCheck, based on the arithmetic result of urinary tissue inhibitor of metalloproteinase 2 (TIMP2) and insulin-like growth factor binding protein 7 (IGFBP7) ([TIMP2]*[IGFBP7]), is the only biomarker test recently approved by the FDA for AKI detection in patients (22, 32). Here, IGFBP7 is linked to acute kidney injury.